Pharvaris N.V.
Status: Publicly traded
Direct answer
Pharvaris N.V. is publicly traded on NASDAQ under the ticker PHVS.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema...
Can you invest in Pharvaris N.V.?
Yes. Pharvaris N.V. is publicly traded on NASDAQ under the ticker PHVS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Pharvaris N.V.
Detailed equity research is provided by MarketSnap.